Data for: Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study

More effective, tolerable interventions for treatment-refractory obsessive-compulsive disorder (OCD) are needed. Preliminary findings encourage optimism that methylphenidate augmentation may be of benefit in the treatment of OCD. To test modulator methylphenidate (MPH) of extended-release formulations (MPH-ER) a safe and effective add-on therapy for refractory OCD, a pilot randomized, placebo-controlled, double-blind trial was conducted at an outpatient, single-center academic setting. Participants included 44 adults with serotonin reuptake inhibitor (SRI) treatment-refractory OCD and receiving a stable fluvoxamine pharmacotherapy with Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores higher than 20.

针对治疗抵抗性强迫症（OCD）所需的更有效、更耐受的干预措施，需求日益迫切。初步研究结果鼓舞人心，甲基苯丙胺增敏疗法可能在OCD治疗中发挥积极作用。为测试长效释放剂型甲基苯丙胺（MPH-ER）作为治疗抵抗性OCD的安全且有效的辅助疗法，本研究在一家单中心学术门诊环境下进行了一项随机、双盲、安慰剂对照的试点试验。参与者包括44名成年患者，他们接受血清素再摄取抑制剂（SRI）治疗抵抗性OCD，并维持稳定剂量的氟伏沙明药物治疗，其耶鲁-布朗强迫症量表（Y-BOCS）评分高于20分。